The South Korea renal cancer therapeutics market size stood at around USD xx billion in 2020 and is projected to reach xx billion by 2028, exhibiting a CAGR of around xx% during the forecast period.
Renal cancer is the second most frequent urogenital tumour after bladder cancer. Of all renal cancers, renal cell carcinoma (RCC) makes up nearly 80–85%. Renal cell carcinoma (RCC) originates in the lining of the proximal convoluted tubule in the kidney that transport primary urine. The most frequently detected pathologic subtype of RCC is clear cell RCC and it makes up 70–80% of all newly diagnosed RCC. Renal cell carcinoma mainly affects the population who are older, usually between ages 50 and 70. It is well known that RCC is not sensitive to chemotherapy or radiation therapy. In Korea, 5-year survival rate for kidney cancer patients has increased over the last few decades.
In Korea, the incidence of renal cancer has increased significantly due to changing lifestyle, aging of the population, alcohol consumption, unhealthy diet, consumption of tobacco, increase in incidence of obesity. 5,945 new cases and 1,442 deaths due to renal cancer were reported in South Korea in 2020. The 5-year prevalence rate was reported to be 34.97 per 100,000 in GLOBOCAN report for year 2020. Ceaselessly increasing burden of the disease is a primary factor propelling the market drive. The mortality rate for kidney cancer is expected to increase with age which shows a positive impact on the market.